- “You do not have middle ears!” exclaimed my middle schooler as our conversation evolved into chatting about the special sense of hearing and balance while discussing the letters of Helen Keller. The following narration describes the reminiscences during conversations that ensued over the next week or so at the dinner table with my wife and our 8- and 12-year-old daughters.
- As humanity grapples with the social, economic, and political disruption caused by the coronavirus disease 2019 (COVID-19) pandemic, many healthcare systems across the globe have been working to set appropriate expectations for patients being treated during these challenging times. As of June 8, 2020, there are close to 2 million COVID-19 cases in the United States with 112,000 deaths [coronavirus.jhu.edu]. As patient volumes increased, healthcare systems and state and federal governments scrambled to address critical shortages of COVID-19 test kits, personal protective equipment, pharmaceutical drugs, and medical equipment such as mechanical ventilators.
- The widespread social and economic disruption caused by the novel coronavirus disease 2019 (COVID-19) is clearly apparent and has affected all walks of life. The biomedical research enterprise is no exception. According to the 2015-2016 Global Participation in Clinical Trials Report published by the US Food and Drug Administration (FDA),1 there were 40,385 clinical trial participants in the United States during that time period. Given exponential advances in biotechnology, it is expected that this number has grown considerably over the past 5 years.